OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach.

ABSTRACT:

Background

Individualized pharmacotherapy requires identification of genetic variants predictive of treatment response. In OPRM1, Asn40Asp has been reported to be predictive of response to naltrexone treatment. Nevertheless, the in vitro function of the polymorphism remains elusive and over 300 OPRM1 sequence variants have been identified to date. Therefore we used a haplotype-based approach to capture information of other genetic variants that might predict treatment response to naltrexone in the COMBINE Study.

Methods

5' nuclease genotyping assays (TaqMan) were applied for 10 SNPs. Five-locus haplotypes in 2 OPRM1 haplotype blocks were assigned to Caucasian participants. The relationship of the haplotypes to medication reflected by "good clinical outcome" was analyzed in 3

SUBMITTER: Oroszi G 

PROVIDER: S-EPMC2679376 | biostudies-literature | 2009 Mar

REPOSITORIES: biostudies-literature